Merck & Company, Inc.

Merck & Company, Inc.

133.72
USD
+0.91
(+0.69%)
0.99EPS
146.31P/E
358.45BMarket Cap
Feb 02Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
15.04
14.88
14.2
14.48
14.88
16.31
15.41
16.41
19.25
23.41
23.06
25.39
26.27
27.28
Basic EPS, GAAP
1.5
4.2
1.6
1.43
0.89
2.4
3.88
2.79
5.16
5.73
0.14
6.77
7.38
0.99
Free Cash Flow per Basic Share
3.98
2.46
4.51
3.77
2.39
4.21
5.29
4.05
5.58
7.54
4.99
8.49
6.66
7.57
Dividend per Share
1.8
1.85
1.84
1.86
1.92
1.99
2.24
2.46
2.61
2.77
2.86
3.1
3.3
3.39
Book Value per Share
17
17.14
16.06
14.58
12.73
10.3
10.2
10.01
15.11
18.12
14.84
18.32
21.26
18.2
Tangible Book Value per Share
4.67
5.38
1.56
1.68
0.69
-1.8
-3.04
-3.03
-2.38
1.78
-0.64
3.27
1.76
-0.62
Basic Weighted Avg Shares
2,928
2,838
2,781
2,749
2,697
2,593
2,539
2,530
2,530
2,532
2,607
2,528
2,475
2,470
Sales/Revenue/Turnover
44,033
42,237
39,498
39,807
40,122
42,294
39,121
41,518
48,704
59,283
60,115
64,168
65,011
67,378
Operating Margin (%)
17.41
15.82
19.11
13.81
16.94
21.12
20.26
13.36
27.1
30.84
4.91
31.51
34.01
9.2
Depreciation Expense
6,988
6,691
6,375
5,471
4,676
4,519
3,310
3,486
3,214
3,909
3,872
4,499
5,838
7,344
Net Income, GAAP
4,404
11,920
4,442
3,920
2,394
6,220
9,843
7,067
13,049
14,519
365
17,117
18,254
2,453
Effective Tax Rate (%)
18.54
30.95
17.44
15.41
62.92
28.82
21.82
22.86
10.96
11.66
80.04
14.06
13.31
48.57
Profit Margin (%)
10
28.22
11.25
9.85
5.97
14.71
25.16
17.02
26.79
24.49
0.61
26.68
28.08
3.64
Working Capital
17,817
14,208
10,550
13,410
6,152
3,669
5,263
437
6,394
11,483
6,474
10,362
15,189
10,140
LT Debt
20,539
18,699
23,829
24,274
21,353
19,806
22,736
25,360
30,690
28,745
33,683
34,462
46,750
49,689
Total Equity
52,326
48,791
44,767
40,308
34,569
26,882
26,001
25,404
38,257
46,058
37,635
46,372
52,662
44,946
Return on Invested Capital (%)
6.28
5.26
7.95
5.87
3.52
10.42
10.68
6.87
17.01
20.97
0.61
21.05
18.97
2.79
Return on Capital (%)
6.44
16.82
7.04
6.58
4.27
12.25
28.33
18.72
22.49
20.74
0.78
23.3
20.94
3.61
Return on Common Equity (%)
8.57
24.22
9.52
9.25
6.43
20.38
37.42
27.59
41.1
34.5
0.87
40.81
36.91
5.07

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
2,444
2,825
4,088
LT Borrowings
46,673
51,081
49,689
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,470
2,469
2,467
Market Capitalization
297,079
317,221
358,447

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
35,015
36,679
38,941
Cash, Cash Equivalents & STI
5,702
7,141
9,650
Accounts Receivable, Net
12,210
12,564
12,744
Inventories
6,479
6,207
6,164
Total Current Liabilities
26,945
27,731
28,801
Payables & Accruals
24,501
24,906
24,713
ST Debt
2,444
2,825
4,088
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.75%
17.89%
13.56%
Free Cash Flow
9.64%
16.57%
-23.27%
Net Income, GAAP
473.39%
918.93%
6.64%
Sales/Revenue/Turnover
5.41%
9.7%
1.31%
Total Cash Common Dividend
4.85%
5.64%
4.29%

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
15,775
16,112
16,657
15,624
64,168
2025
15,529
15,806
17,276
16,400
65,011
2026
16,286
16,607
18,085
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.88
2.15
1.25
1.48
6.77
2025
2.02
1.77
2.33
1.2
7.38
2026
-1.72
-0.54
2.05
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.77
0.78
0.77
0.77
3.1
2025
0.81
0.83
0.82
0.82
3.3
2026
0.85
0.87
0.85
- -
- -

Company Description

CEO
Robert M. Davis
Full Time Employees
75,000
Sector
Health technology
Industry
Pharmaceuticals: major
Address
126 East Lincoln Avenue Rahway NJ United States 07065
IPO Date
Jan 1, 1941
Website
merck.com
Business
Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, is a leading research-intensive biopharmaceutical company that discovers, develops, manufactures, and markets prescription medicines, vaccines, biologic therapies, and animal health products worldwide; key human health offerings include oncology drugs such as Keytruda (pembrolizumab), the PD-1 inhibitor generating $29.5 billion in 2024 revenues for various cancers, Lynparza (olaparib), a PARP inhibitor for BRCA-mutated ovarian cancer, vaccines like Gardasil (HPV vaccine, $8.6 billion in 2024 revenues), ProQuad/M-M-R II/Varivax (MMRV combination vaccine, $2.5 billion in 2024 revenues), and additional products including Cancidas (caspofungin acetate) antifungal, Januvia/Janumet for diabetes, and veterinary pharmaceuticals, vaccines, and health management solutions for livestock and companion animals. Headquartered in Rahway, New Jersey, and founded over 130 years ago, the company operates globally across human health and animal health segments, targeting patients, healthcare providers, and animal health customers in major markets including the United States, Europe, Asia, and emerging regions. Recent developments include a November 2025 research and development funding agreement with Blackstone Life Sciences for $700 million to advance sacituzumab tirumotecan (sac-TMT), an investigational TROP2-targeted antibody-drug conjugate in 15 Phase 3 trials for breast, endometrial, and lung cancers; multiyear manufacturing expansions totaling nearly $6 billion across North Carolina, Delaware, Kansas, and Virginia to boost vaccine, biologic, and Keytruda production capacity as part of a broader $70 billion U.S. investment commitment; and a launched $3 billion restructuring plan emphasizing productivity savings and U.S.-based R&D and manufacturing enhancements.

Company News

  • 11,187 Merck & Co., Inc. $MRK Shares Purchased by Allianz SE

  • Merck & Co., Inc. $MRK Stake Reduced by Barrow Hanley Mewhinney & Strauss LLC

  • 1 High-Flying Stock to Buy Hand Over Fist if the Stock Market Crashes

  • Merck Reports Positive Survival Data For Investigational Therapy for Advanced Gastric Cancer

  • HALO Faces Legal Setback in Germany Over MRK's Keytruda SC, Stock Down

  • Merck's drug prolongs survival in advanced stomach, esophageal cancers in trial

  • Halozyme Stock Slides, European Patent Fight With Merck Spurs Fresh Pressure

  • Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know

  • Merck & Co., Inc. (MRK) Presents at Jefferies London Healthcare Conference Transcript

  • Merck & Co. Eyes Kidney Cancer Data as Vaccine Research Expands Beyond Melanoma

  • Merck and Isomorphic Labs Enter Strategic Research Collaboration

  • Insider Selling: Merck & Co., Inc. (NYSE:MRK) EVP Sells $8,611,961.85 in Stock

  • Bristol Myers vs. Merck: Which Big Pharma Stock Is the Better Buy?

  • Merck Ends Nemtabrutinib Development: What's Next for Its Pipeline?

  • Thomas H. Glocer to Retire From Merck Board of Directors in May 2027; Douglas M. Baker, Jr. Appointed Independent Lead Director

  • Merck stops trials of blood cancer drug after risk assessment

  • Merck Announces Update on BELLWAVE Clinical Development Program Evaluating Nemtabrutinib

  • Merck Announces First-Quarter 2027 Dividend

  • Forget SCHD: 4 Dividend Stocks Retirees Should Own Instead

  • Merck & Co., Inc. (NYSE:MRK) Share Price Breaks Below Fifty Day Moving Average Following Insider Selling